Discussion on clinical pharmacology of novel anti-obesity drugs:glucagon-like peptide-1 receptor agonists
WANG Jing
LI Li
WEI Chun-min
Abstract：With the rising global prevalence of obesity,the limitations of lifestyle interventions and traditional anti-obesity drugs have become increasingly prominent,making the research and development of novel anti-obesity drugs a focal point in this field.Glucagon-like peptide-1(GLP-1)receptor agonists and their derived dual-target drugs,relying on their significant anti-obesity efficacy and relatively good safety profile have emerged as an effective therapeutic regimen for obese patients.This article summarizes the clinical pharmacology factors of these anti-obesity drugs,including their pharmacokinetic and pharmacodynamic characteristics,exposure-response relationships,immunogenicity,medication in special populations,and the influence of intrinsic and extrinsic factors.It focuses on elaborating key issues such as PK optimization strategies,dosage regimen selection,and drug-drug interactions.The purpose of this article is to summarize the research priorities of clinical pharmacology for this class of drugs and provide a comprehensive overview for domestic research and development institutions.
Keywords：glucagon-like peptide-1 receptor agonistsobesityclinical pharmacologyimmunogenicity
Publication Date：2025-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2502-2507 )